- IVX-A12 (a bivalent of IVX-121 for RSV and IVX-241 for hMPV) progressing in Phase 1, and the only clinical-stage candidate targeting these two leading causes of pneumonia in one combination - ...
Patronus Biotech today announced a grant from the Gates Foundation to accelerate the development of its novel malaria vaccine and adjuvant program to support affordable access and use in global health ...
BOSTON and CHENGDU, China, Jan. 08, 2024 (GLOBE NEWSWIRE) -- HilleVax, Inc. (HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, and Chengdu ...
Platform to advance the large-scale production and purification of virus-like particles (VLPs) for use in cost-effective human vaccines Sunflower Therapeutics (Sunflower), a public benefit corporation ...
Study successfully met its primary endpoints Data from second pivotal Phase 3 study in people aged 12 to 64 years expected in the third quarter 2023 COPENHAGEN, Denmark, June 20, 2023 – Bavarian ...
– No evidence of immune interference; initial indication of combinability achievable with company’s VLP technology – – Next steps: Icosavax plans to initiate a Phase 2 immunogenicity trial for IVX-A12 ...
The chikungunya virus virus-like particle (CHIKV VLP) vaccine achieved 100% seroconversion in adults who had previously received alphavirus vaccines and alphavirus vaccine–naive control individuals, ...
– IVX-A12 induced robust immune responses at Day 28 to both RSV and hMPV, and was generally well tolerated, consistent with prior IVX-A12 Phase 1 data – SEATTLE, Dec. 11, 2023 (GLOBE NEWSWIRE) -- ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback